Blood compatibility testing
Mikael Häggström [note 1]
Upon direct testing by adding antibodies against A, B and/or Rh to patient blood, agglutination means that the patient has the antigen tested. Upon indirect testing by adding A or B antigen to patient plasma, agglutination means absence of the antigen in the patient (and thus the patient produces antibodies against it).
Other blood group systems
In the antibody screening procedure, an individual's plasma is added to a panel of two or three sets of red blood cells which have been chosen to express most clinically significant blood group antigens. Agglutination of the screening cells by the plasma, with or without the addition of anti-human globulin, indicates that an unexpected blood group antibody is present. If this occurs, further testing using more cells (usually 10–11) is necessary to identify the antibody. By examining the antigen profiles of the red blood cells the person's plasma reacts with, it is possible to determine the antibody's identity.
The image above shows the interpretation of an antibody panel used to detect antibodies towards the most relevant blood group antigens. Each row represents "reference" or "control" red blood cells of donors which have known antigen compositions and are ABO group O. A + means that the antigen is present on the reference red blood cells, and 0 means it is absent; nt means "not tested". The "result" column to the right displays reactivity when mixing reference red blood cells with plasma from the patient in 3 different phases: room temperature, 37°C and AHG (with anti-human globulin, by the indirect antiglobulin test).
- Step 1; Annotated in blue: starting to exclude antigens without reaction in all 3 phases; looking at the first reference cell row with no reaction (0 in column at right, in this case cell donor 2), and excluding (here marked by X) each present antigen where the other pair is either practically non-existent (such as for D) or 0 (presence is homozygous, in this case homozygous c).
When both pairs are + (heterozygous cases), they are both excluded (here marked by X), except for C/c, E/e, Duffy, Kidd and MNS antigens (where antibodies of the patient may still react towards blood cells with homozygous antigen expression, because homozygous expression results in a higher dosage of the antigen). Thus, in this case, E/e is not excluded in this row, while K/k is, as well as Jsb (regardless of what Jsa would have shown).[note 2]
- Step 2: Annotated in brown: Going to the next reference cell row with a negative reaction (in this case cell donor 4), and repeating for each antigen type that is not already excluded.
- Step 3: Annotated in purple. Repeating the same for each reference cell row with negative reaction.
- Step 4: Discounting antigens that were absent in all or almost all reactive cases (here marked with \). These are often antigens with low prevalence, and while there is a possibility of such antibodies being produced, they are generally not the type that is responsible for the reactivity at hand.
- Step 5: Comparing the remaining possible antigens for a most likely culprit (in this case Fya), and selectively ruling out significant differential antigens, such as with the shown additional donor cell type that is known to not contain Fya but contains C and Jka.
In this case, the antibody panel shows that anti-Fya antibodies are present. This indicates that donor blood typed to be negative for the Fya antigen must be used. Still, if a subsequent cross-matching shows reactivity, additional testing should be done against previously discounted antigens (in this case potentially E, K, Kpa and/or Lua).
|Neutralizing substance||Antigen cancelled|
|Guinea pig urine||Sda|
When multiple antibodies are present, or when an antibody is directed against a high-frequency antigen, the normal antibody panel procedure may not provide a conclusive identification. In these cases, hemagglutination inhibition can be used, wherein a neutralizing substance cancels out a specific antigen. Alternatively, the plasma may be incubated with cells of known antigen profiles in order to remove a specific antibody (a process termed adsorption); or the cells can be treated with enzymes such as ficain or papain which inhibit the reactivity of some blood group antibodies and enhance others (see table below).
People who have tested positive for an unexpected blood group antibody in the past may not exhibit a positive reaction on subsequent testing; however, if the antibody is clinically significant, they must be transfused with antigen-negative blood regardless.
Following is a comparison of clinically relevant characteristics of antibodies against the main human blood group systems:
|Most common in immediate hemolytic transfusion reactions||A||Yes||Fya||Jka|
|Most common in delayed hemolytic transfusion reactions||E,D,C||Jka|
|Most common in hemolytic disease of the newborn||Yes||D,C||Yes|
|Commonly produce intravascular hemolysis||Yes||Yes||Yes|
|Reactive at room temperature||Yes||M,N||Lea, Leb||P1|
|Nearly always clinically insignificant||Yes||M,N||Yes||P1|
|Enhanced by ficain and papain||Yes||Yes||Yes||Yes||P1||Yes|
|Destroyed by ficain and papain||Fya, Fyb||Yes||Yes|
|Displaying dosage Further information: Blood compatibility testing||Cc, Ee||Yes||Yes||Yes|
- ↑ For a full list of contributors, see article history. Creators of images are attributed at the image description pages, seen by clicking on the images. See Patholines:Authorship for details.
- ↑ Besides from C/c, E/e, Duffy, Kidd and MNS, clinically significant dosage effects is rare but not impossible for other antigens, which thus may still be considered if subsequent cross-matching is reactive.
- ↑ 1.0 1.1 Justin R. Rhees, M.S., MLS(ASCP)CM, SBBCM. Introduction to Antibody Identification. University of Utah, Medical Laboratory Sciences.
- ↑ 2.0 2.1 2.2 2.3 Mais, Daniel (2014). Quick compendium of clinical pathology . United States: American Society for Clinical Pathology Press. ISBN 978-0-89189-615-9. OCLC 895712380.
- ↑ Uhl, L (11 Jan 2021). Pretransfusion testing for red blood cell transfusion. UpToDate.
- ↑ 4.0 4.1 Hill, Ben C.; Hanna, Courtney A.; Adamski, Jill; Pham, Huy P.; Marques, Marisa B.; Williams, Lance A. (2017). "Ficin-Treated Red Cells Help Identify Clinically Significant Alloantibodies Masked as Reactions of Undetermined Specificity in Gel Microtubes ". Laboratory Medicine 48 (1): 24–28. doi:10.1093/labmed/lmw062. ISSN 0007-5027. PMID 28007780.
- ↑ 5.0 5.1 Eric Ching. Questions and Answers on Proteolytic Enzymes Used in Blood Group Serology. Canadian Society for Transfusion Medicine.